Nxera Pharma and Antiverse Collaborate to Develop Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Collaboration Announcement:
Nxera Pharma and Antiverse have entered a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs) using Antiverse’s generative AI antibody design platform.

Technology Combination:
The collaboration combines Antiverse’s generative AI antibody design expertise with Nxera’s NxWave platform, a powerful tool for GPCR target selection, validation, and structural determination.

Project Focus:
The first project aims to design antibodies with agonistic function for a challenging GPCR target.

Financial Terms:
Antiverse will receive an upfront payment and research funding and is eligible for milestone payments. Nxera will retain an exclusive worldwide license to the antibody assets, providing full rights to develop and commercialize the candidates.

Unmet Need:
The partnership aims to bring transformative therapies for multiple diseases of high unmet need, addressing the challenge of undrugged GPCRs with known disease links.

Company Backgrounds:

Nxera Pharma:
A technology-powered biopharma company focused on developing new specialty medicines for unmet needs in Japan and globally, with an extensive pipeline of over 30 active programs.

Antiverse:
An artificial intelligence-driven techbio company specializing in antibody design against challenging targets, including GPCRs and ion channels, with a strong internal pipeline of antibodies against several challenging drug targets.